Biogen leads the $18 billion global MS market with Avonex and Tysabri, and the launch of Tecfidera secures the firm's dominance for at least the next several years.
Tecfidera's safety and efficacy profile and its oral administration are making it the go-to option for first-line MS patients, allowing for multi-billion-dollar peak sales potential.
Biogen launched two hemophilia drugs in 2014, which should help diversify revenue and further boost sales growth sparked by Tecfidera. Read more
Avonex is losing its edge as the leading MS drug, as similar competitors nip at its heels, novel oral therapies launch, and the prospect of generic Copaxone looms.
Tysabri's efficacy could be overshadowed by worrisome side effects as additional cases of PML are reported in Tysabri users and as patients who test positive for the JC virus antibody discontinue therapy.
XenoPort, Alkermes, and Forward Pharma are developing drugs that are similar to Tecfidera but may be able to bypass Tecfidera's patents, and their entry could shorten Tecfidera's growth trajectory. Read more
We award Biogen a Standard Stewardship Rating. James C. Mullen, who worked his way up to CEO and chairman of Biogen before the merger, served as Biogen Idec's CEO and president until his retirement in June 2010. George Scangos took over as CEO in July Read more
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's leading cancer drug Rituxan. Today, Rituxan and next-generation Read more
The Sector Is Fairly Valued, but These Stocks Are Not Watch more